Platelet mitochondrial DNA methylation predicts future cardiovascular outcome in adults with overweight and obesity

Table 2 MtDNA methylation thresholds for each CpG site and score for predicting CVD outcome

a. Threshold for each CpG site
	Methylation	Median survival time (months)^*	At risk	CVD during follow-up	CVD free	Log-rank P value
All patients		43.8	200	84	116
MT-CO1 nt6809 (% methylation)	< 12.0	47.5	114	35	79	0.049
MT-CO1 nt6809 (% methylation)	≥ 12.0	38.3	83	47	36	0.049
MT-CO3 nt9444 (% methylation)	< 1.5	47.0	146	44	102	0.001
MT-CO3 nt9444 (% methylation)	≥ 1.5	33.0	51	38	13	0.001
MT-TL1 nt3254 (% methylation)	< 3.0	45.7	105	37	68	0.22
MT-TL1 nt3254 (% methylation)	≥ 3.0	42.1	94	46	48	0.22
Cholesterol ratio	< 3.5	42.1	102	43	59	0.38
Cholesterol ratio	≥ 3.5	45.3	94	41	53	0.38
b. Score for predicting the CVD outcome
Score**	Median survival time (months)	At risk	CVD during follow-up	CVD-free	% CVD-developed at follow-up	Log-rank P value
0	~ 60	61	13	48	21%	0.003
1	54.8	63	21	42	33%
2	35.1	69	45	24	65%

(a) MtDNA methylation thresholds for each CpG site and outcomes of survival analysis. Survival analysis for the participants stratified according to the methylation score at individual loci (MT-CO1, MT-CO3, and MT-TL1) and to the cholesterol ratio. (b) Score to predict future CVD events based on methylation at MT-CO1 nt6809, MT-CO3 nt9444, and MT-TL1 nt3254.
*Median: time in months without-CVD
**Participants with score 2 (two or three CpG sites with methylation above the thresholds) had a lower median time without-CVD (35.1 months) than the participants with score 1 (54.8 months) and score 0 (the median survival time is not reached). This analysis was performed on a total of 193 participants, for whom the methylation percentage of all the three genes was available

ISSN: 1868-7083